Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Reata Pharma
(NQ:
RETA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 25, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Reata Pharma
< Previous
1
2
3
4
5
6
Next >
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
March 06, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
REATA PHARMACEUTICALS INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA
March 03, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
FDA Grants Approval of Reata Pharmaceuticals’ (NASDAQ: RETA) SKYCLARYS Drug, Making the First and Only Drug for Friedreich’s Ataxia
March 01, 2023
Reata Pharmaceuticals, Inc. (NASDAQ: RETA) is engaged as a biopharmaceutical company, which is focused on the research, development and commercialization
Via
Spotlight Growth
Exposures
Product Safety
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
February 28, 2023
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
November 10, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
November 08, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
October 31, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022
October 20, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich’s Ataxia
October 13, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference
September 06, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
August 09, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
August 08, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022
August 01, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors
July 11, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
May 26, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
NASDAQ:RETA Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Reata Pharmaceuticals, Inc.
May 10, 2022
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Reata Pharmaceuticals, Inc.
Via
SBWire
Reata Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
May 10, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. to Report First Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on May 10, 2022
May 02, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
March 31, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
February 28, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome
February 25, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
Final Deadline Alert: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
February 18, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Reata Pharmaceuticals, Inc. To Report Fourth Quarter and Full Year 2021 Financial Results and To Provide an Update on Development Programs on February 28, 2022
February 18, 2022
From
Reata Pharmaceuticals, Inc.
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (RETA)
February 17, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Deadline Tomorrow Alert: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
February 17, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
REATA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals Inc. and Encourages Investors to Contact the Firm
February 16, 2022
From
Bragar Eagel & Squire
Via
Business Wire
Deadline Friday Notice: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
February 16, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Deadline Friday Alert: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
February 15, 2022
Los Angeles - (NewMediaWire) - February 15, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Reata Pharmaceuticals, Inc....
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Friday Deadline Reminder: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
February 14, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
FINAL DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action RETA
February 12, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.